Payment overview · 2025
General Payments
$721.43
36 reported records · 13 companies
Healthcare provider profile · identity verified
Zheni Avram, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND, VA · NPI 1215113196
Verified facts
What the public records show
CMS Open Payments records show Zheni Avram, M.D. received $721.43 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $277.43 | 38.5% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $214.04 | 29.7% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $54.60 | 7.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.94 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.18 | 2.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.37 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.72 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.37 | 2.4% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $17.09 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.76 | 2.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.29 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.83 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.81 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $721.43 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $156.59 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.32 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $119.53 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.83 | 11 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $54.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 932 | 258 |
| Levothyroxine Sodium | Levothyroxine Sodium | 576 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 565 | 155 |
| Losartan Potassium | Losartan Potassium | 516 | 136 |
| Hydrochlorothiazide | Hydrochlorothiazide | 410 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 107 |
| Lisinopril | Lisinopril | 339 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 281 | 73 |
| Simvastatin | Simvastatin | 280 | 82 |
| Ezetimibe | Ezetimibe | 265 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 54 |
| Metformin Hcl | Metformin Hcl | 207 | 65 |
| Omeprazole | Omeprazole | 204 | 56 |
| Sertraline Hcl | Sertraline Hcl | 195 | 49 |
| Gabapentin | Gabapentin | 184 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 55 |
| Metformin Hcl Er | Metformin Hcl | 171 | 49 |
| Montelukast Sodium | Montelukast Sodium | 168 | 49 |
| Alendronate Sodium | Alendronate Sodium | 166 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 46 |
| Trazodone Hcl | Trazodone Hcl | 148 | 37 |
| Potassium Chloride | Potassium Chloride | 123 | 41 |
| Atenolol | Atenolol | 113 | 26 |
| Eliquis | Apixaban | 112 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 112 | 29 |
| Synthroid | Levothyroxine Sodium | 108 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 94 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 23 |
| Azithromycin | Azithromycin | 92 | 82 |
| Furosemide | Furosemide | 89 | 32 |
| Ozempic | Semaglutide | 89 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 24 |
| Jardiance | Empagliflozin | 83 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 17 |
| Bupropion Xl | Bupropion Hcl | 80 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 23 |
| Famotidine | Famotidine | 74 | 22 |
| Carvedilol | Carvedilol | 70 | 17 |
| Valsartan | Valsartan | 70 | 19 |
| Donepezil Hcl | Donepezil Hcl | 69 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 20 |
| Glimepiride | Glimepiride | 66 | 21 |
| Meloxicam | Meloxicam | 66 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 16 |
| Warfarin Sodium | Warfarin Sodium | 63 | 12 |
| Azelastine Hcl | Azelastine Hcl | 61 | 26 |
| Cefuroxime | Cefuroxime Axetil | 61 | 44 |
| Glipizide Er | Glipizide | 61 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 13 |
| Benazepril Hcl | Benazepril Hcl | 54 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 12 |
| Spironolactone | Spironolactone | 48 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 12 |
| Allopurinol | Allopurinol | 47 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 14 |
| Alprazolam | Alprazolam | 44 | 28 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | 13 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 30 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 19 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 17 |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 29 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 30 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Diazepam | Diazepam | 31 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 20 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Prednisone | Prednisone | 24 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Estradiol | Estradiol | 20 | 11 |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Verapamil Sr | Verapamil Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Baclofen | Baclofen | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Wegovy | Semaglutide | 14 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $721.43 · 36 records | ABBVIE INC. | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FREESTYLE LIBRE 3, Fluad, Flucelvax, INCEPTIV, INSPIRE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, Sunosi, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error